Callos Andrew 4

4 · CYTOKINETICS INC · Filed Mar 17, 2026

AI-generated summary of this filing

Updated Mar 17, 2026

Cytokinetics (CYTK) EVP Andrew Callos Receives Equity Award

What Happened

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), was granted a mix of restricted stock units (RSUs) and stock options on 2026-03-15. The grants, reported on a Form 4 filed 2026-03-17, consist of 20,646 RSUs, 13,320 RSUs (special supplemental award), 1,665 stock option units (derivative), and 29,480 stock option units (derivative) — a total of 65,111 equity awards. All awards show an acquisition price of $0 (grants/awards, not purchases).

Key Details

Transaction date: 2026-03-15; Form 4 filed: 2026-03-17 (appears timely).
Awards and prices:
- 20,646 RSUs (F1) — $0 acquisition price.
- 13,320 RSUs (F2, special supplemental award) — $0 acquisition price.
- 1,665 stock options (F3, derivative) — $0 acquisition price.
- 29,480 stock options (F4, derivative) — $0 acquisition price.
Vesting/terms (from filing footnotes):
- F1 RSUs: convert 1:1 to common stock; vest 40% at year 1, 40% at year 2, 20% at year 3 (subject to continued employment).
- F2 RSUs: convert 1:1; vest 50% at year 1 and 50% at year 2 (subject to continued employment).
- F3 & F4 stock options: vest in 48 equal monthly installments (subject to continued employment).
Shares owned after the transaction: not specified in the summary information provided.
No 10b5-1 plan, tax withholding, or late-filing flag noted in the provided details.

Context

These are compensation grants (awards), not open-market purchases or sales. RSUs convert to shares on the stated vesting schedule; stock options are derivative awards that will vest monthly over four years. Such awards are typical executive compensation and do not by themselves indicate a buy or sell decision in the market.

Form 4

Period: 2026-03-15

EVP, Chief Commercial Officer

Transactions

Award
Common Stock
[F1]
2026-03-15+20,646→ 68,504 total
Award
Common Stock
[F2]
2026-03-15+13,320→ 81,824 total
Award
Incentive Stock Option (Right to Buy)
[F3]
2026-03-15+1,665→ 1,665 total
Exercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (1,665 underlying)
Award
Non-Qualified Stock Option (Right to Buy)
[F4]
2026-03-15+29,480→ 29,480 total
Exercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (29,480 underlying)

Footnotes (4)

[F1]Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
[F2]Special supplemental equity award comprised of restricted stock units ("RSUs" that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 50% of the RSUs on the 1-year anniversary of the grant date and 50% of the RSUs on the 2-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
[F3]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
[F4]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

Signature

/s/ John O. Faurescu, attorney-in-fact for Mr. Callos|2026-03-17

1 file